Hui-Ping Lin1,2, Shih Sheng Jiang2,3, Chih-Pin Chuu1,2,4*
1 Institute of Cellular and System Medicine, National Health Research Institutes, Miaoli, Taiwan, 2 Translational Center for Glandular Malignancies, National Health Research Institutes, Miaoli, Taiwan, 3National Institute of Cancer Research, National Health Research Institutes, Miaoli, Taiwan, 4Graduate Program for Aging, China Medical University, Taichung, Taiwan
Caffeic acid phenethyl ester (CAPE) treatment suppressed proliferation, colony formation, and cell cycle progression in PC-3 human prostate cancer cells. CAPE decreased protein expression of cyclin D1, cyclin E, SKP2, c-Myc, Akt1, Akt2, Akt3, total Akt, mTOR, Bcl-2, Rb, as well as phosphorylation of Rb, ERK1/2, Akt, mTOR, GSK3a, GSK3b, PDK1; but increased protein expression of KLF6 and p21Cip1. Microarray analysis indicated that pathways involved in cellular movement, cell death, proliferation, and cell cycle were affected by CAPE. Co-treatment of CAPE with chemotherapeutic drugs vinblastine, paclitaxol, and estramustine indicated synergistic suppression effect. CAPE administration may serve as a potential adjuvant therapy for prostate cancer.
* THESE STATEMENTS HAVE NOT BEEN EVALUATED BY THE FOOD AND DRUG ADMINISTRATION. THIS IS NOT INTENDED TO DIAGNOSE, TREAT CURE OR PREVENT ANY DISEASE.